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 Induction of Brain Tumor Stem Cell
Apoptosis by FTY720: A Potential
Therapeutic Agent for Glioblastoma
Estrada-Bernal A, Palanichamy K, Chaudhury AR, et al.
Neuro Oncol 2012; 14: 405–15.
Although their existence has remained somewhat enigmatic,
the identification and selective therapeutic elimination of
glioma stem cells or initiating cells remains a focus of current
research in neuro-oncology. In the April issue, another phar-
macological approach to target specifically the stem cell com-
partment in glioblastoma was proposed. FTY720 is a sphin-
gosine analogue that decreases the levels of G protein-cou-
pled sphingosine-1-phosphate receptors. This drug was ap-
proved for the treatment of multiple sclerosis in 2010. It
shows high blood-brain barrier permeation and should there-
fore in principle be capable of targeting glioma cells shielded
by the blood-brain barrier. Estrada-Bernal et al report that
FTY720 inactivates the ERK/MAP kinase pathway, induces
the BH3-only protein Bim and, in terms of cell death induc-
tion, does so in synergy with temozolomide. These effects
were demonstrated specifically in “brain tumour stem cells”.
Furthermore, FTY720 inhibited the growth of intracranial xe-
nograft tumours transplanted in nude mice, too. Admittedly,
as in multiple sclerosis, it remains somehow unclear how pre-
cisely FTY720 is inducing its therapeutic effect. This will
probably be the subject of further studies. Yet, given that the
drug is already available and tolerated by human patients, it
may represent a valid option for clinical evaluation in patients
with refractory glioblastoma.
 Soluble Factors Secreted by Glioblasto-
ma Cell Lines Facilitate Recruitment,
Survival and Expansion of Regulatory
T Cells: Implications for Immunotherapy
Crane CA, Ahn BJ, Seunggu J, et al. Neuro Oncol 2012; 14:
584–95.
Immunotherapeutic approaches to glioblastoma experience a
revival at present, with multiple smaller vaccination trials on-
going and the epidermal growth factor receptor vIII peptide
vaccination entering randomized phase-II and -III trials. Yet,
the immune privilege of glioblastoma conferred by an immu-
nosuppressive microenvironment created by these tumours
represents a major obstacle for immunotherapy. In the May
issue of Neuro-Oncology, Crane et al readdress the role of
soluble mediators released by glioblastoma cells and specifi-
cally examine their effects on regulatory T cells, a major im-
munosuppressive T cell population. There was an increase in
the frequency of regulatory T cells in the tumour tissue as
opposed to the periphery in glioblastoma patients. The chemo-
kine CCL22 induced the migration of regulatory T cells more
effectively than that of conventional T cells. Yet, interfering
with CCL22 signalling at the receptor level did not com-
pletely block T cell migration, suggesting that factors other
than CCL22 are involved in this process. The authors also
found a correlation between tumour burden and regulatory T
cell populations in the peripheral blood, reinforcing the idea
(that has never been proven) that immunotherapy will work
better in glioblastoma patients with minimal residual disease.
This study illustrates once more how glioblastomas maintain
their micromilieu in an immunosuppressed state and shows
that the balance between immunosuppressive and immuno-
stimulatory signals must be altered to facilitate tumour cell
recognition and attack by the immune system.
 Treatment-Related Myelodysplasia in
Patients with Primary Brain Tumors
Baehring JM, Marks PW. Neuro Oncol 2012; 14: 529–40.
The life expectancy of many glioma patients, notably suffer-
ing from non-glioblastoma gliomas, is probably increasing,
due to improved techniques in neurosurgery and radiotherapy
as well as an increasing repertoire of medical treatments, and
also improved post-treatment surveillance and symptomatic
treatment. At the same time, more patients are treated with
alkylating-agent chemotherapy up-front whereas radio-
therapy is delayed. Therefore, as outlined in a comprehensive
overview by Baehring and Marks in the May issue, treatment-
related myelodysplastic syndrome (t-MDS) and treatment-re-
lated acute myelogenous leukemia (t-AML) require attention
during long-term follow-up. In that regard, the EORTC study
22033, which compares radiotherapy with protracted dose-
dense temozolomide in patients with low-grade gliomas, will
be particularly helpful for estimating the risk of such compli-
cations. So far, the risk for t-MDS and t-AML remains low
among glioma patients, but the occasional practice of main-
taining patients on alkylating-agent chemotherapy for more
than a year or even until progression should be discouraged
until appropriate data indicate a survival benefit from such
prolonged chemotherapy regimens.
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